MDC Stock Overview
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Medlab Clinical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$6.90 |
| 52 Week High | AU$13.50 |
| 52 Week Low | AU$0.086 |
| Beta | 1.1 |
| 11 Month Change | 0% |
| 3 Month Change | -0.72% |
| 1 Year Change | -41.77% |
| 33 Year Change | -78.10% |
| 5 Year Change | -90.98% |
| Change since IPO | -76.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.9% |
| 1Y | -41.8% | 11.0% | 18.4% |
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -11.1% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned -0.5% over the past year.
Price Volatility
| MDC volatility | |
|---|---|
| MDC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: MDC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Sean Hall | www.medlab.co |
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.
Medlab Clinical Limited Fundamentals Summary
| MDC fundamental statistics | |
|---|---|
| Market cap | AU$15.07m |
| Earnings (TTM) | -AU$8.32m |
| Revenue (TTM) | AU$1.54m |
9.8x
P/S Ratio-1.8x
P/E RatioIs MDC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDC income statement (TTM) | |
|---|---|
| Revenue | AU$1.54m |
| Cost of Revenue | AU$336.29k |
| Gross Profit | AU$1.20m |
| Other Expenses | AU$9.52m |
| Earnings | -AU$8.32m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.64 |
| Gross Margin | 78.11% |
| Net Profit Margin | -541.67% |
| Debt/Equity Ratio | 0% |
How did MDC perform over the long term?
See historical performance and comparison